Table 3. Isolates received by the New York State public health laboratory, Wadsworth Center, Albany, NY, USA, from clinical laboratories for the purpose of identifying or excluding Candida auris, through April 30, 2017*.
| Organism, no. isolated | Clinical laboratories’ identification system |
Wadsworth Center identification using MALDI-TOF MS, no. isolates‡ | |||
|---|---|---|---|---|---|
| API | VITEK 2 | VITEK MS† | Other | ||
|
Candida haemulonii, 38 |
|
36 |
|
1§ | C. auris, 35 |
| 1¶ |
C. haemulonii, 1; Candida duobushaemulonii, 1; Candida glabrata,1 |
||||
| No identification, 13 |
2 |
2 |
9 |
|
C. auris, 11 |
|
C. glabrata, 2 | |||||
|
C. auris, 6 |
|
|
|
6§ |
C. auris, 5 |
|
C. duobushaemulonii, 1 | |||||
|
Candida famata, 5 |
1 |
3 |
|
1# |
C. guilliermondii, 1; C. lusitaniae, 1; Candida parapsilosis, 2; Candida fermentati, 1 |
|
Candida glabrata, 1 |
|
1 |
|
|
C. glabrata, 1 |
|
Candida guilliermondii, 1 |
|
1 |
|
|
C. guilliermondii, 1 |
|
Candida lusitaniae, 1 |
|
1 |
|
|
C. lusitaniae, 1 |
|
Candida sphaerica, 1 |
|
1 |
|
|
Saccharomyces cerevisiae, 1 |
|
Cryptococcus laurentii, 1 |
|
1 |
|
|
Cryptococcus neoformans, 1 |
|
C. neoformans, 1 |
|
1 |
|
|
S. cerevisiae, 1 |
|
C. famata/C. guilliermondii, 1 |
|
1 |
|
|
C. parapsilosis, 1 |
|
C. famata/C. parapsilosis, 1 |
|
1 |
|
|
C. parapsilosis, 1 |
|
C. famata/C. parapsilosis/
Candida tropicalis, 1 |
|
1 |
|
|
C. parapsilosis, 1 |
|
Candida dubliniensis/C. haemulonii, 1 |
|
1 |
|
|
C. glabrata, 1 |
|
C. lusitaniae/Candida utiliz, 1 |
|
|
1 |
|
C. lusitaniae, 1 |
|
Candia sphaerica/Rhodotorula glutinis/ Rhodotorula mucilaginosa/C. laurentii, 1 |
|
1 |
|
|
C. parapsilosis, 1 |
|
Zygosaccharomyces bailii/C. sake/C. famata/Candida lipolytica, 1 |
|
1 |
|
|
C. glabrata, 1 |
|
S. cerevisiae, 23 |
7 |
16 |
|
|
S. cerevisiae, 23 |
| Trichosporon mucoides, 1 | 1 | T. mucoides, 1 | |||
*API, bioMérieux, Inc., Durham, NC, USA; MALDI-TOF MS, Bruker Daltonics, Inc., Billerica, MA, USA; VITEK 2, bioMérieux, Durham, NC, USA; VITEK MS, bioMérieux, Solna, Sweden. MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight; MS, mass spectrometry. †No C. auris entry. ‡Research use only library was expanded in-house by adding 10 C. auris isolates comprising clades I–IV (CDC-AR bank, https://www.cdc.gov/drugresistance/resistance-bank/index.html) and 8 C. auris isolates from New York in 2016 comprising clades I and II. §MALDI-TOF MS, research use only library with 3 C. auris entries. ¶BD Phoenix Automated Microbiology System (BD Diagnostics, Sparks, MD, USA). #RapID YEAST PLUS System (Thermo Fisher Scientific, Waltham, MA, USA).